Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Feasibility of Interventions on People Who Inject Drugs in Vietnam (DRIVE-IN)

20. august 2018 opdateret af: ANRS, Emerging Infectious Diseases

Feasibility of an Interventional Project to Reduce HIV Incidence Among People Who Inject Drugs in Haiphong, Viet Nam

This study aims at assessing the feasibility of implementing an interventional cohort of people who inject drugs in Haiphong, Viet Nam.

For this purpose, the investigators will conduct a RDS survey to i) assess the current situation of drug use behaviour, HIV and Hepatitis C Virus (HCV) infection in the study population and ii) recruit participants for the longitudinal phase. The latter will consist of enroling the most difficult to reach People Who Inject Drugs (PWID) (those not followed by health centers), including early injectors, Men who have Sex with Men (MSM) and female sex workers (FSW) and following them up for 6 months in order to estimate the follow-up rate and preliminary estimates of HIV and HCV incidence.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Detaljeret beskrivelse

Objectives:

The primary objective of the DRIVE-IN project is to evaluate the feasibility of implementing an interventional cohort of PWID in Haiphong. Such a cohort (DRIVE) will be instrumental in demonstrating the efficacy of a community-involved intervention integrating prevention and care in order to reduce HIV and HCV transmission among PWID in Haiphong.

The main expected result of DRIVE-IN is to demonstrate that enrolment and follow-up of various hard-to-reach subgroups of PWID is feasible in the local context. These feasibility objectives will be evaluated using a set of relevant indicators.

Design:

The research will first include a respondent-driven sampling (RDS) survey, including a maximum of 600 PWID. Then 250 RDS participants (i.e about a quarter of the future DRIVE cohort) will be selected for a longitudinal study, with an enrolment and 3 follow-up visits at week 4, 12 and 24. In parallel, four qualitative studies will be implemented: one study to explore how to reach the hardest-to-reach and most-at-risk PWID, one feed-back study on PWID feeling about their participation in the research, one study investigating the reasons of drop-outs, and a final study on the research process itself.

Endpoints:

The RDS will describe the target population and the patterns of drug use. The feasibility of implementing an interventional cohort will be evaluated on several indicators:

  • International multi-disciplinary research network is operational
  • Completion of recruitment within the time frame
  • Follow-up rate >80% at 24 weeks
  • Implementation and increased access to peer-led interventions
  • Establishment of a data management center
  • Improved laboratory capacities for research
  • Documented support of local and national authorities

Study population RDS survey Inclusion criteria Age > 18 years Self-reported drug injector confirmed by a positive urinary test and either skin marks of injection or knowledge of injecting procedures Signed informed consent Non-inclusion criteria Unable of understanding informed consent and answering questionnaires

Longitudinal study Inclusion criteria Having participated to the RDS survey Signed informed consent specific to the longitudinal study Non-inclusion criteria Ongoing Methadone Maintenance Therapy (MMT) Ongoing antiretroviral therapy Health status not compatible with study follow-up Have a plan to move out of Haiphong over the next two years. Have been sentenced recently to a prison term

Follow-up and study visits contents:

Participants of the longitudinal phase will be followed at week 4, 12 and 24 (final visit). During the RDS, face-to-face questionnaires will be applied on drug use, sexual health, and referral to care and repeated at each follow-up visit, along with the record of medical events. In addition, a urinary test will be collected at the RDS to assess the range of recent drugs used, and repeated at the final follow-up visit (week 24). Finally, at the RDS and final visit, HIV, HCV, Hepatitis B Virus (HBV) serology will be done along with appropriate counselling.

Sample size:

  • 603 PWID will be enrolled in the RDS survey
  • 250 RDS participants will be enroled in the longitudinal phase, including:
  • 140 PWID for > 2 years, including females
  • 50 recent injectors (< 2 years from first injection)
  • 30 FSW who inject drugs
  • 30 MSM who inject drugs

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

603

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Hai Phong, Vietnam
        • Hai Phong Medical University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

People who inject drugs living in Haiphong, Vietnam. The longitudinal phase will be restricted to those not followed by health care services, i.e. not taking methadone nor antiretroviral therapy

Beskrivelse

  • Inclusion criteria

    • Being more than 18 years of age
    • Being drug injector confirmed by a positive urine drug test with knowledge of injecting procedures
    • Having signed the informed consent form
    • For the Longitudinal study - having participated in the RDS survey
  • Exclusion criteria

    • Unable to understand informed consent and how to answer a questionnaire
    • For the longitudinal study - being under methadone maintenance therapy and antiretroviral treatment
    • Having a health condition not compatible with study follow-up
    • Plan to move away from Haiphong in the next 2 years
    • Serving a sentence in prison

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Cohort Participants Attending the Last Follow-up Visit at W52
Tidsramme: 52 weeks
Number of participants who were followed up and not lost to follow-up after enrolment into cohort.
52 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
HCV Seroconversion
Tidsramme: 52 weeks
Number of new HCV infection among HCV negative (at RDS) cohort participants over 1 year period
52 weeks
HIV Seroconversion
Tidsramme: 52 weeks
Number of new HIV infection among HIV negative (at RDS) cohort participants over 1 year period.
52 weeks
Incidence of HCV Infection
Tidsramme: 52 weeks
The HCV incidence was calculated by 100person/year
52 weeks
HIV Incidence
Tidsramme: 52 weeks
HIV incidence was calculated by 100person/year. With zero conversion, we choose 2.5% unilateral confidence interval.
52 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Nicolas Nagot, MD,PhD, INSERM U1058 & University of Montpellier, France
  • Ledende efterforsker: Oanh Khuat Thi, MD, MSc, Supporting Community Development Initiatives (SCDI)
  • Ledende efterforsker: Don DesJarlais, PhD, Mount Sinai Beth Israel

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. september 2014

Primær færdiggørelse (Faktiske)

1. juni 2015

Studieafslutning (Faktiske)

1. juni 2016

Datoer for studieregistrering

Først indsendt

22. september 2015

Først indsendt, der opfyldte QC-kriterier

9. oktober 2015

Først opslået (Skøn)

12. oktober 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. august 2018

Sidst verificeret

1. august 2018

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ANRS12299 DRIVE IN
  • P30DA011041 (U.S. NIH-bevilling/kontrakt)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner